Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24738624 | 0.80 | AHR (0.36) | ARELANETTRPSMB8AHR | |
| SCHEMBL21638122 | 0.76 | AHR (0.54) | ARELANETAAR1TTRAHR | |
| SCHEMBL24738630 | 0.76 | AHR (0.39) | ARELANETTRPSMB8AHR | |
| SCHEMBL14374957 | 0.75 | KMT2A (0.50) | ELANETAAR1GAAAHRMEN1 | |
| SCHEMBL29658023 | 0.74 | ELANE (0.41) | ELANETTRPSMB8AHRMEN1 | |
| SCHEMBL22884332 | 0.74 | ELANE (0.41) | ELANETTRPSMB8AHRMEN1 | |
| SCHEMBL23288190 | 0.74 | C1R (0.41) | ELANETTRPSMB8AHRMEN1 | |
| SCHEMBL28739208 | 0.74 | AR (0.40) | ARTTRCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL19802457 | 0.74 | MEN1 (0.50) | ARTTRPSMB8MEN1KMT2A | |
| SCHEMBL24738570 | 0.72 | AHR (0.39) | ARELANETTRPSMB8AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240352003-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME AND COMPOSITION FOR ORGANIC MATERIAL LAYER | LT MATERIALS CO., LTD. (KR) | 2024-10-24 | — | — | US | disclosed |
| EP-4074706-A1 | DEUTERATED HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME AND COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT EMITTING DEVICE | LG Display Co., Ltd. (KR) | 2022-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352003-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME AND COMPOSITION FOR ORGANIC MATERIAL LAYER | CYP1A1, CYP1B1, CYP2E1 | AR 2623/4885ELANE 2507/4885TAAR1 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.